Related references
Note: Only part of the references are listed.Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Kyriakos P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase Ib Dose-Escalation Study (PX-171-006) of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Progressive Multiple Myeloma
Ruben Niesvizky et al.
CLINICAL CANCER RESEARCH (2013)
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies
David Siegel et al.
HAEMATOLOGICA (2013)
Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety
A. Z. Badros et al.
LEUKEMIA (2013)
Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting
Aaron Ciechanover
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2012)
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Ravi Vij et al.
BLOOD (2012)
Aphase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
David S. Siegel et al.
BLOOD (2012)
A selective inhibitor of the immunoproteasome subunit LMP2 induces apoptosis in PC-3 cells and suppresses tumour growth in nude mice
M. Wehenkel et al.
BRITISH JOURNAL OF CANCER (2012)
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib
Ravi Vij et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Specific Cell-Permeable Inhibitor of Proteasome Trypsin-like Sites Selectively Sensitizes Myeloma Cells to Bortezomib and Carfilzomib
Anne C. Mirabella et al.
CHEMISTRY & BIOLOGY (2011)
Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events
Shirin Arastu-Kapur et al.
CLINICAL CANCER RESEARCH (2011)
Effect of Cytochrome P450 3A4 Inducers on the Pharmacokinetic, Pharmacodynamic and Safety Profiles of Bortezomib in Patients with Multiple Myeloma or Non-Hodgkin's Lymphoma
Andrzej Hellmann et al.
CLINICAL PHARMACOKINETICS (2011)
Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)
D. J. Kuhn et al.
CURRENT CANCER DRUG TARGETS (2011)
Pharmacokinetics, Pharmacodynamics, Metabolism, Distribution, and Excretion of Carfilzomib in Rats
Jinfu Yang et al.
DRUG METABOLISM AND DISPOSITION (2011)
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy
Lawrence R. Dick et al.
DRUG DISCOVERY TODAY (2010)
Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements
Shivanni Kummar et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Proteasomes in immune cells: more than peptide producers?
Marcus Groettrup et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors
Deborah J. Kuhn et al.
BLOOD (2009)
Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
Francesco Parlati et al.
BLOOD (2009)
Selective Inhibitor of Proteasome's Caspase-like Sites Sensitizes Cells to Specific Inhibition of Chymotrypsin-like Sites
Matthew Britton et al.
CHEMISTRY & BIOLOGY (2009)
A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies
Owen A. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis
Tony Muchamuel et al.
NATURE MEDICINE (2009)
Prospective comparison of subcutaneous versus intravenous administration of bortezomib in patients with multiple myeloma
Philippe Moreau et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study
J. F. San-Miguel et al.
LEUKEMIA (2008)
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myelorna
Deborah J. Kuhn et al.
BLOOD (2007)
Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome
Susan D. Demo et al.
CANCER RESEARCH (2007)
Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells
M. Kraus et al.
LEUKEMIA (2007)
Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
Richard I. Fisher et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib
D Chauhan et al.
CANCER CELL (2005)
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
PG Richardson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Bortezornib in recurrent and/or refractory multiple myeloma - Initial clinical experience in patients with impaired renal function
S Jagannath et al.
CANCER (2005)
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer
CN Papandreou et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies
RZ Orlowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)